Idarubicin
From Wikipedia, the free encyclopedia
Idarubicin
|
|
Systematic (IUPAC) name | |
9-acetyl-7-( 4-amino-5-hydroxy-6-methyl- tetrahydropyran-2-yl) oxy-6,9, 11-trihydroxy- 7,8,9,10-tetrahydrotetracene-5,12-dione | |
Identifiers | |
CAS number | |
ATC code | L01 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | C26H27NO9 |
Mol. mass | 497.494 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Protein binding | 97% |
Metabolism | ? |
Half life | 22 hours |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Idarubicin or 4-demethoxydaunorubicin is an anthracycline drug that is used in the treatment of cancer. It belongs to the family of drugs called antitumor antibiotics. FDA approved label can be found here. It is distributed under trade name Zavedos.